Viz.ai’s Artificial Intelligence Technology Assessed for PE Detection

September 21, 2023—Viz.ai, a developer of artificial intelligence (AI)–powered disease detection and intelligent care coordination technology, announced new clinical data supporting advancements in pulmonary embolism (PE) detection.

According to the company, the real-world clinical efficacy of Viz.ai’s PE Module to quickly, accurately identify PE and associated right heart strain, accelerate care coordination, and improve health care workflow efficiency was demonstrated in two studies:

• “Automated PE Clot Detection and RV/LV Ratio Measurement using AI-based Deep Learning Algorithms: A Preliminary Validation Study,” presented by Parth Rali, MD, at the PERT Consortium’s 9th annual Pulmonary Embolism Symposium held September 21-23 in Austin, Texas.
• “The Use of Artificial Intelligence Technology in the Detection and Treatment of Pulmonary Embolism at a Tertiary Referral Center,” presented by Jacob Shapiro, MD, at Midwestern Vascular 2023, the 48th annual meeting of the Midwestern Vascular Surgical Society held September 7-9 in Minneapolis, Minnesota.

The first study evaluated the performance of Viz PE and Viz right ventricle/left ventricle (RV/LV) algorithms. The preliminary validation study found that, across 100 retrospectively collected chest CT pulmonary angiography images, Viz PE demonstrated a sensitivity of 91.1% and specificity of 100%. Additionally, the study revealed a significant positive correlation between algorithmic and manual calculation of RV/LV ratio.

“Our preliminary findings underscore the remarkable performance of Viz PE and Viz RV/LV,” commented Dr. Rali in the company’s press release. “We are excited to partner with Viz.ai and pioneer investigator-initiated research that will reveal the impact of AI technology in revolutionizing patient care.” Dr. Rali is Associate Professor of Thoracic Medicine and Surgery at Lewis Katz School of Medicine at Temple University in Philadelphia, Pennsylvania.

The second study demonstrated how Viz PE directly improves patient wait times for evaluation. The investigators found that adoption of Viz.ai’s technology significantly reduced time to consult on average from 4 hours to 6 minutes, leading to faster diagnosis and initiation of treatment. When combined with multidisciplinary evaluation by an existing Pulmonary Embolism Response Team (PERT), time to radiology report was reduced by 109 minutes, showcasing the potential combined benefits of AI technology and the PERT model of care on PE care and management.

“The integration of AI technology into our PE workflow has significantly shortened the time-to-consult, helping us to promptly evaluate and triage these potentially unstable patients,” commented Dr. Shapiro in Viz.Ai’s press release. “This advancement has the possibility to reshape the landscape of PE management.” Dr. Shapiro is a vascular surgery resident at TriHealth in Cincinnati, Ohio.